Pilot study evaluates safety and efficacy of low-dose enoxaparin in psoriasis, suggesting a potential new treatment option.
Background: Psoriasis is an inflammatory skin condition that manifests as red, plaque-like lesions that are often covered with silvery-white scales. It is a chronic and recurrent immune-mediated skin disease. Aim and objectives: To assess the safety and effectiveness of treating plaque psoriasis with low doses of enoxaparin. Patients and methods: This study was conducted on 30 patients with plaque psoriasis(43.3%) males and(56.7%) females with a mean age of (37.7±13) years, ranging between(18-59) years, the patients had a mean disease duration (5.1±3.6) years, ranged between (1-16) years. Each patient was treated by 5mg enoxaparin(Clexane) as a subcutaneous injection once a week for 12 weeks. Results: There was statistically significant improvement in clinical response as 6 patients(20%) showed significant change, 12 patients(40%) showed moderate change, 8 patients (26.7%) showed no significant change, and finally, 4 patients(13.3%) were worsened. Conclusion: The excellent side-effect profile of low-dose enoxaparin makes it a promising new therapeutic choice for psoriasis. Concerning efficacy, additional large-scale trials are needed to ascertain the optimal dose and length of treatment, the subgroup of psoriasis to be treated, and to compare enoxaparin to conventional psoriasis remedies.
No takes yet. Share an insight, caveat, or question.
Zaky et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: